RxDoctor Payments Data

Brian Sucheski, MD

Ophthalmology · Chalfont, PANPI 1801827159

Payments from drug & device makers

$947in general payments, 2019–2025

Across 42 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$177
  • Harrow Eye, LLC$123
  • Sun Pharmaceutical Industries Inc.$110
  • Kala Pharmaceuticals, Inc.$102
  • Tarsus Pharmaceuticals, Inc.$77
  • Bausch & Lomb Americas Inc.$73
  • plus $286 from 7 others

What the payments were for

  • Food & beverage$947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$947 in reported general payments places this provider in the 40th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$434,189
Medicare patients
1,276
Services billed
2,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost125$60,987
RestasisCyclosporine23$36,481
Tobradex StTobramycin/Dexamethasone134$30,617
Timolol Maleate163$16,992
RocklatanNetarsudil Mesylat/Latanoprost29$14,989
ProlensaBromfenac Sodium35$12,031
Cyclosporine24$11,807
Brimonidine Tartrate68$11,504
MieboPerfluorohexyloctane/Pf14$10,249
RhopressaNetarsudil Mesylate20$9,856
Timolol MaleateTimolol Maleate/Pf13$8,661
Travoprost48$8,620
VyzultaLatanoprostene Bunod14$7,973
Travatan ZTravoprost16$7,924
IlevroNepafenac21$7,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$52$97,468148 claims
Eyevance Pharmaceuticals LLCTobradex St$13$30,617134 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$73$18,22228 claims
NovartisTravatan Z, Ilevro$177$15,61137 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$40$12,03135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Chalfont

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →